Patents by Inventor Stephen Galli

Stephen Galli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220227859
    Abstract: The present invention relates to the treatment of type 2 inflammation or mast-cell dependent disease. The inventors showed that, when exposed to domestic allergic alarms, activation of TRPV1+Tac1+ nociceptor-MRGPRB2+ MC sensory clusters might represent a key early event controlling the development of frequent mast cell-dependent allergic disorders. The human ortholog of MRGPRB2 (MRGPRX2) can thus be a good target to treat type 2 inflammation or mast cell-dependent disorders. Thus, the present relates to a MRGPRX2 inhibitor for use in the treatment of a type 2 inflammation or mast cell-dependent disorders in a subject in need thereof.
    Type: Application
    Filed: May 15, 2020
    Publication date: July 21, 2022
    Inventors: Nicolas GAUDENZIO, Stephen GALLI
  • Publication number: 20200011865
    Abstract: The present invention relates to methods and kits for detecting basophil cells activation. The inventors showed that fluorescent avidin binds to basophil cell surface upon degranulation and that this probe can be used to monitor basophil degranulation More specifically the present invention relates to methods for monitoring of basophil degranulation using avidin-based probes. The method of the invention described here allows to measure direct basophil degranulation following Fc?RI crosslinking with allergen. This method provides a direct measurement of degranulation by staining exteriorized granules and unambiguously detects activated basophils degranulated. The extent of the degranulation can be directly deduced from the intensity of fluorescence of fluorochrome-labelled avidin measured on basophils. When applied to allergic patient samples the avidin-based method detected efficiently specific basophil responses.
    Type: Application
    Filed: December 15, 2017
    Publication date: January 9, 2020
    Inventors: Eric ESPINOSA, RĂ©gis JOULIA, Salvatore VALITUTTI, Kaori MUKAI, Mindy TSAI, Nicolas GAUDENZIO, Stephen GALLI
  • Publication number: 20060037089
    Abstract: Non-human transgenic animal models and cells derived therefrom are provided for RabGEF1 function. RabGEF1 is a negative regulator of Fc?RI-dependent mast cell activation and T cell activation via the T cell receptor and a lack of RabGEF1 results in the development of skin inflammation in vivo. The mast cells derived from such animals exhibit enhanced Ras-mediated signaling and functional responses when activated through high affinity IgE receptors. These cells show significant potentiation of IgE and antigen-dependent secretion of 3 classes of mast cell mediators, providing a useful source of mast cells for screening assays.
    Type: Application
    Filed: June 21, 2005
    Publication date: February 16, 2006
    Inventors: Mindy Tsai, See-Ying Tam, Stephen Galli